NeuroVive Pharmaceutical AB
Biomedical Center
Sölvegatan 19
SE-221 84 Lund
Tel: 46-0-46-288-0110
Fax: 46-0-46-888-8348
Website: http://www.neurovive.com/
Email: info@neurovive.com
About NeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical is a pioneer in mitochondrial research and development. The focus is on developing drug candidates that maintain mitochondrial integrity and improves their function for indications with unmet medical needs. Research and development is conducted both in-house and in collaboration with renowned international partners.YEAR FOUNDED:
2000
LEADERSHIP:
Founder: Eskil Elmér
CEO: Erik Kinnman
CSO and Founder: Eskil Elmér
159 articles about NeuroVive Pharmaceutical AB
-
NeuroVive Pharmaceutical AB Year End Report January - December 2019
2/19/2020
NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study
-
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
12/20/2019
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the completed recruitment of healthy volunteers in the second part of the company's ongoing Phase Ia/b clinical study with candidate drug KL1333, in development for chronic oral treatment of primary mitochondrial disease.
-
NeuroVive Announces Settlement in Dispute With CicloMulsion AG
12/16/2019
NeuroVive Pharmaceutical AB announced that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology.
-
NeuroVive Pharmaceutical AB Interim Report January - September 2019
11/20/2019
NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study
-
NeuroVive Pharmaceutical AB Interim Report January - June 2019
8/21/2019
The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT.
-
Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019
8/20/2019
Presentations will be made by members of NeuroVive's management and board as well as by external authorities in genetic mitochondrial diseases.
-
NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation
7/27/2019
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to severe traumatic brain injury, TBI, has received Fast Track designation from the US Food and Drug Administration, FDA, facilitating its clinical development and path forwards to market.
-
NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study
7/4/2019
NeuroVive Pharmaceutical AB announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study with KL1333, NeuroVive's candidate drug for chronic treatment of genetic mitochondrial diseases, following successful completion of the first part.
-
NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
5/10/2019
NeuroVive Pharmaceutical AB announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT in development for treatment of moderate to severe traumatic brain injury, TBI.
-
NeuroVive Pharmaceutical AB Publishes 2018 Annual Report
3/25/2019
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website www.neurovive.com.
-
NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study
3/19/2019
NeuroVive Pharmaceutical AB today announced that the first healthy volunteer in the company's KL1333 phase Ia/b study has been screened and will be enrolled into the study.
-
NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
11/15/2018
NeuroVive Pharmaceutical AB announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova, Sweden's innovation agency, and the Swelife call, for intensified development in the NVP015 project, the goal of which is to advance the candidate compound NV354 to clinical studies.
-
NeuroVive Receives KL1333 Clinical Trial Regulatory Approval
10/10/2018
NeuroVive Pharmaceutical AB today announced that it has received approval of its clinical trial application concerning a planned phase I KL1333 study in patients and healthy volunteers from the UK regulatory authority, Medicines and Healthcare products Regulatory Agency (MHRA).
-
NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI
10/4/2018
NeuroVive Pharmaceutical AB today announced the successful completion of biomarker analyses of samples from its clinical study in severe traumatic brain injury patients (the CHIC study) using the company's investigational compound NeuroSTAT.
-
NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan
9/6/2018
NeuroVive Pharmaceutical AB today announced positive U.S. Food and Drug Administration (FDA) feedback on its NeuroSTAT clinical development plan for the treatment of moderate to severe Traumatic Brain Injury (TBI) at a pre-IND (Investigational New Drug) meeting.
-
NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia
8/28/2018
NeuroVive Pharmaceutical AB today announced that scientists at the company's research partner the Children's Hospital of Philadelphia (CHOP) have received a three-year grant (W81XWH-17-PRMRP-TTDA), in total of $4,090,281 USD, from the U.S. Department of Defense
-
NeuroVive Pharmaceutical AB Interim Report January - June 2018
8/21/2018
NeuroVive out-licenses targeted LHON therapy to BridgeBio
-
NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics
6/18/2018
NeuroVive Pharmaceutical AB and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under NeuroVive's NVP015 program
-
Amended Increase Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)
5/31/2018
NeuroVive Pharmaceutical AB announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharmaceutical AB, approved at the Extraordinary General Meeting on 22 March 2018.
-
NeuroVive Pharmaceutical AB Interim Report January - March 2018
5/22/2018
NeuroVive decided to conduct a rights issue for the continued development of the company's drug projects following shareholder approval at an Extraordinary General Meeting.